Results 181 to 190 of about 10,998,800 (355)

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Efficacy of various extent of resection on survival rates of patients with pilocytic astrocytoma: based on a large population

Scientific Reports
Pilocytic astrocytoma (PA) is classified as a Grade I benign neuroglial tumor. The extent of surgical resection is a critical factor influencing the prognosis for patients with PA.
Jun Su, Shanshan Guo, Zheyuan Chen, Yiming Han, Jingwang Yan, Qiyun Tang, Yu Mao, Haiqiang Zhang, Guojiang Hou, Gaopan Dong, Chao Guo, Pengfei Yang   +11 more
doaj   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Targeted Antiplatelet Therapy

Platelets, 1994
R S, More, M J, Underwood, A H, Gershlick   +2 more
openaire   +2 more sources

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature, 2022
C. Vellano, M. G. White, M. Andrews, M. Chelvanambi, R. Witt, J. Daniele, M. Titus, J. McQuade, F. Conforti, E. Burton, Matthew Lastrapes, G. Ologun, Alexandria P. Cogdill, Golnaz Morad, P. Prieto, A. Lazar, Yanshuo Chu, Guangchun Han, M. A. Khan, Beth A. Helmink, M. Davies, R. Amaria, Jeffrey J Kovacs, S. Woodman, S. Patel, P. Hwu, M. Peoples, Jeffrey E. Lee, Z. Cooper, Haifeng Zhu, G. Gao, H. Banerjee, M. Lau, J. Gershenwald, A. Lucci, E. Keung, M. Ross, L. Pala, E. Pagan, R. Segura, Qian Liu, Mikayla S. Borthwick, Eric K. Lau, M. Yates, S. Westin, K. Wani, M. Tetzlaff, L. Haydu, Mikhila Mahendra, Xiaoyan Ma, Christopher Logothetis, Zachary J Kulstad, Sarah B. Johnson, C. Hudgens, Ningping Feng, L. Federico, G. Long, P. Futreal, Swathi Arur, H. Tawbi, Amy E. Moran, Linghua Wang, T. Heffernan, J. Marszalek, J. Wargo   +64 more
semanticscholar   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Transcription factor 19‐mediated epigenetic regulation of FOXM1/AURKB axis contributes to proliferation in clear cell renal carcinoma cells

MedComm, 2023
Yakun Luo, Qing Shi, Lu Wang, Shuijie Li, Wanhai Xu   +4 more
doaj   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source